Published in Blood Weekly, November 4th, 2004
"We are very pleased with the progress we have achieved with CG53135 for oral mucositis and look forward to sharing the results of our phase I program at ASH," stated William Hahne, MD, vice president of clinical development at CuraGen. "The clinical data we have obtained has sparked the interest of several investigators who are eager to work with us in phase II, and we are in the process of making the necessary preparations to transition the...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Blood Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.